文章：

利用循环血浆miRNA在甲状腺微小乳头状癌中进行诊断与侵袭性评估

Diagnosis and Evaluation of Aggressiveness Using Circulating Plasma miRNAs in Papillary Thyroid Microcarcinoma

原文发布日期：21 June 2025

DOI: 10.3390/cancers17132079

类型: Article

开放获取: 是

英文摘要：

Background/Objectives:MicroRNAs are emerging as valuable diagnostic markers for various diseases, including papillary thyroid carcinoma (PTC). However, there is limited research on circulating miRNA expression in papillary thyroid microcarcinoma (PTMC). Therefore, we conducted a study to explore whether plasma-derived miRNAs can distinguish PTMC from benign nodules or predict aggressiveness.Methods:A total of 150 patients who underwent thyroidectomy from January 2013 to July 2021 were enrolled in this study. Patients were divided into three groups: benign, low-risk PTMC, and advanced PTMC. Nine patients from each group were selected for microarray analysis for plasma miRNAs. Six miRNAs were selected for comparison of expression levels using TaqMan assay. The ROC curve was utilized to evaluate the diagnostic and aggressiveness value of the miRNAs.Results:From the microarray analysis, miR-455-3p and miR-548ac were identified as miRNAs that can significantly differentiate between benign nodules and PTMC. A combination of six miRNAs (miR-455-3p, miR-548ac., miR-221, miR-222, miR-146a. miR-146b) rather than individual miRNAs had the highest AUC (0.857), sensitivity (0.867), and specificity (0.800) in differentiating benign and PTMC. In microarray analysis, no significant miRNAs were observed to distinguish between low-risk group and aggressive PTMC. However, in the six-miRNA combination, it was possible to distinguish low-risk PTMC from aggressive PTMC with an AUC of 0.763, sensitivity of 0.739, and the specificity of 0.727.Conclusions:A combination of six miRNAs presents the possibility of distinguishing between benign and PTMC and low-risk and aggressive PTMC with an acceptable AUC, sensitivity, and specificity.

摘要翻译： 

背景/目的：微小RNA正逐渐成为包括甲状腺乳头状癌在内的多种疾病的重要诊断标志物。然而，目前关于甲状腺微小乳头状癌循环miRNA表达的研究较为有限。为此，本研究旨在探讨血浆来源的miRNA能否有效区分甲状腺微小乳头状癌与良性结节，或预测其侵袭性。 方法：本研究共纳入2013年1月至2021年7月期间接受甲状腺切除术的150例患者。患者被分为三组：良性结节组、低风险甲状腺微小乳头状癌组和进展性甲状腺微小乳头状癌组。每组选取9例患者进行血浆miRNA芯片分析，并筛选出6种miRNA通过TaqMan检测进行表达水平比较。采用ROC曲线评估miRNA的诊断价值及对侵袭性的预测效能。 结果：芯片分析显示，miR-455-3p和miR-548ac能显著区分良性结节与甲状腺微小乳头状癌。六种miRNA联合检测组合（miR-455-3p、miR-548ac、miR-221、miR-222、miR-146a、miR-146b）在区分良恶性病变时表现出最佳诊断效能，其曲线下面积为0.857，灵敏度为0.867，特异度为0.800。芯片分析中未发现能显著区分低风险组与侵袭性甲状腺微小乳头状癌的miRNA，但六种miRNA联合检测可有效区分两者，其曲线下面积为0.763，灵敏度为0.739，特异度为0.727。 结论：六种miRNA联合检测能以可接受的曲线下面积、灵敏度和特异度区分甲状腺良性结节与微小乳头状癌，以及低风险与侵袭性甲状腺微小乳头状癌。

原文链接：

Diagnosis and Evaluation of Aggressiveness Using Circulating Plasma miRNAs in Papillary Thyroid Microcarcinoma